All filters
Slidesets
Improving access to and utilization of viral load testing for better patient management- Pascale Ondoa, MD, MSc, PhD
Presented at:
INTEREST 2018
Slidesets
Tuberculosis epidemiology and prospects for control- Jeremiah Chakaya Muhwa, MD
Presented at:
INTEREST 2018
Slidesets
Contrasting cultures of TB and HIV- Nesri Padayatchi, MBChB, DCH, DTM&H, DPH, DHSM, MS, PhD
Presented at:
INTEREST 2018
Slidesets
Hepatitis elimination in SSA: what will it take?- Ganiyat Oyeleke, MD
Presented at:
INTEREST 2018
Slidesets
Multigenerational mentorship 'for impact'- Elizabeth Bukusi, MBChB, MMed, MPH, PhD, PGD, MBE
Presented at:
INTEREST 2018
Slidesets
Pilot implementation of point of care early infant hiv diagnosis in Kenya- Collins Odhiambo
Presented at:
INTEREST 2018
Slidesets
A cross-country unit cost analysis of community-based HIV selftest kit distribution in Malawi, Zambia and Zimbabwe- Collin Mangenah
Presented at:
INTEREST 2018
Meeting
INTEREST 2018
Meeting
European HIV Clinical Forum 2017
Slidesets
State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc
Presented at:
European HIV Clinical Forum 2017
Slidesets
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık
Presented at:
European HIV Clinical Forum 2017
Slidesets
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia
Presented at:
European HIV Clinical Forum 2017
Slidesets
French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin
Presented at:
European HIV Clinical Forum 2017